Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced a strategic collaboration with TARA Mind, working alongside Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The partnership aims to expand mental health awareness within the veteran community and leverage the networks of TARA Mind and VETS to enhance veteran engagement in clinical research. This initiative aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, underscoring the importance of addressing mental health challenges among veterans.
Helus Pharma is advancing its HLP003 program, which has received FDA Breakthrough Therapy Designation, and its broader pipeline of novel serotonergic agonists designed to address unmet mental health needs. The collaboration with TARA Mind and VETS is expected to facilitate access to a population that may benefit from innovative treatments for major depressive disorder. By partnering with organizations that have established trust within the veteran community, Helus Pharma aims to improve recruitment efficiency and raise awareness about the availability of clinical trials.
The company’s proprietary NSAs (novel serotonergic agonists) are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, offering potential durable improvements in mental health. Helus Pharma is currently developing HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, with an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland, and is committed to transforming the treatment landscape for depression, anxiety, and other mental health conditions.
For more information on the full press release, visit https://ibn.fm/o9dCH. Updates and further details about Helus Pharma are available at www.helus.com or by following the team on X, LinkedIn, YouTube, and Instagram. The latest news and updates relating to HELP can be found in the company’s newsroom at https://ibn.fm/HELP.
